Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0273 Transporter Info
Gene Name SLC30A4
Transporter Name Zinc transporter 4
Gene ID
7782
UniProt ID
O14863
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Chemical Compound

  DT Modulation1

 NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC30A4 mRNA [12]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 Valproic Acid results in increased methylation of SLC30A4 gene [20]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation1

 SLC30A4 protein results in increased transport of Zinc [21]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation1

 NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC30A4 mRNA [12]

Regulation Mechanism

 Transcription Factor Info

  4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC30A4 mRNA [12]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC30A4 mRNA [12]

Regulation Mechanism

 Transcription Factor Info

  abrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 abrine results in decreased expression of SLC30A4 mRNA [13]

Regulation Mechanism

 Transcription Factor Info

  Cadmium Chloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Cadmium Chloride results in decreased expression of SLC30A4 mRNA [15]

Regulation Mechanism

 Transcription Factor Info

  chromium hexavalent ion

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 chromium hexavalent ion results in decreased expression of SLC30A4 mRNA [16]

Regulation Mechanism

 Transcription Factor Info

  di-n-butylphosphoric acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 di-n-butylphosphoric acid affects the expression of SLC30A4 mRNA [17]

Regulation Mechanism

 Transcription Factor Info

  dorsomorphin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC30A4 mRNA [12]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC30A4 mRNA [12]

Regulation Mechanism

 Transcription Factor Info

  epigallocatechin gallate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 potassium chromate(VI) co-treated with epigallocatechin gallate results in decreased expression of SLC30A4 mRNA [18]

Regulation Mechanism

 Transcription Factor Info

  Manganese

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 sodium arsenite results in increased abundance of Arsenic co-treated with manganese chloride results in increased abundance of Manganese results in decreased expression of SLC30A4 mRNA [14]

Regulation Mechanism

 Transcription Factor Info

  manganese chloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 sodium arsenite results in increased abundance of Arsenic co-treated with manganese chloride results in increased abundance of Manganese results in decreased expression of SLC30A4 mRNA [14]

Regulation Mechanism

 Transcription Factor Info

  methylmercuric chloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 methylmercuric chloride results in decreased expression of SLC30A4 mRNA [4]

Regulation Mechanism

 Transcription Factor Info

  potassium chromate(VI)

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 potassium chromate(VI) co-treated with epigallocatechin gallate results in decreased expression of SLC30A4 mRNA [18]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 potassium chromate(VI) results in decreased expression of SLC30A4 mRNA [18]

Regulation Mechanism

 Transcription Factor Info

  sodium arsenite

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 sodium arsenite affects the methylation of SLC30A4 gene [19]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 sodium arsenite results in decreased expression of SLC30A4 mRNA [11]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation3

 sodium arsenite results in increased abundance of Arsenic co-treated with manganese chloride results in increased abundance of Manganese results in decreased expression of SLC30A4 mRNA [14]

Regulation Mechanism

 Transcription Factor Info

  triphenyl phosphate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 triphenyl phosphate affects the expression of SLC30A4 mRNA [17]

Regulation Mechanism

 Transcription Factor Info

  Vanadium

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Vanadium results in decreased expression of SLC30A4 mRNA [7]

Regulation Mechanism

 Transcription Factor Info

Carcinogen

  Arsenic

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 sodium arsenite results in increased abundance of Arsenic co-treated with manganese chloride results in increased abundance of Manganese results in decreased expression of SLC30A4 mRNA [14]

Regulation Mechanism

 Transcription Factor Info

Approved Drug

  Folic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Folic Acid inhibits the expression of SLC30A4 [1]

  Panobinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Panobinostat increases the expression of SLC30A4 [2]

  Doxorubicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Doxorubicin inhibits the expression of SLC30A4 [3]

  Valproic Acid

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Valproic Acid increases the expression of SLC30A4 [4]

Drug in Phase 3 Trial

  torcetrapib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 torcetrapib increases the expression of SLC30A4 [8]

Drug in Phase 2 Trial

  Colforsin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Colforsin increases the expression of SLC30A4 [6]

Drug in Phase 1 Trial

  Sodium arsenite

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Sodium arsenite inhibits the expression of SLC30A4 [11]

Drug in Preclinical Test

  (+)-JQ1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 (+)-JQ1 increases the expression of SLC30A4 [9]

Investigative Drug

  Phenylmercuric Acetate

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Phenylmercuric Acetate increases the expression of SLC30A4 [2]

Natural Product

  Coal Ash

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Coal Ash inhibits the expression of SLC30A4 [7]

Environmental toxicant

  Zinc

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Zinc increases the expression of SLC30A4 [5]

Regulation Mechanism

 via enhancement of Metal regulatory transcription factor 1 (MTF1) Transcription Factor Info

Cell System

 Human papillomavirus-related endocervical adenocarcinoma cells (HeLa M)

Health and Environmental Toxicant

  Lead

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Lead affects the expression of SLC30A4 [10]
References
1 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92.
2 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
3 Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
4 Stem Cell Transcriptome Responses and Corresponding Biomarkers That Indicate the Transition from Adaptive Responses to Cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
5 Zinc-dependent lysosomal enlargement in TRPML1-deficient cells involves MTF-1 transcription factor and ZnT4 (Slc30a4) transporter. Biochem J. 2013 Apr 15;451(2):155-63.
6 Induction of zinc transporters by forskolin in human trophoblast BeWo cells. Reprod Toxicol. 2006 Apr;21(3):285-91.
7 Endothelial effects of emission source particles: acute toxic response gene expression profiles. Toxicol In Vitro. 2009 Feb;23(1):67-77.
8 Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. BMC Syst Biol. 2012 Dec 10;6:152.
9 Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
10 RNA-Seq of Human Neural Progenitor Cells Exposed to Lead (Pb) Reveals Transcriptome Dynamics, Splicing Alterations and Disease Risk Associations. Toxicol Sci. 2017 Sep 1;159(1):251-265.
11 Dynamic alteration in miRNA and mRNA expression profiles at different stages of chronic arsenic exposure-induced carcinogenesis in a human cell culture model of skin cancer. Arch Toxicol. 2021 Jul;95(7):2351-2365.
12 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
13 Integration of transcriptomics, proteomics and metabolomics data to reveal the biological mechanisms of abrin injury in human lung epithelial cells. Toxicol Lett. 2019;312:1-10.
14 Using transcriptomic signatures to elucidate individual and mixture effects of inorganic arsenic and manganese in human placental trophoblast HTR-8/SVneo cells. Toxicol Sci. 2025;203(2):216-226.
15 High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. Environ Health Perspect. 2024;132(4):47002.
16 Review of transcriptomic responses to hexavalent chromium exposure in lung cells supports a role of epigenetic mediators in carcinogenesis. Toxicol Lett. 2019;305:40-50.
17 Association between Organophosphate Ester Exposure and Insulin Resistance with Glycometabolic Disorders among Older Chinese Adults 60-69 Years of Age: Evidence from the China BAPE Study. Environ Health Perspect. 2023;131(4):47009.
18 Epigallocatechin-3-gallate (EGCG) protects against chromate-induced toxicity in vitro. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):166-75.
19 Microarray dataset of transient and permanent DNA methylation changes in HeLa cells undergoing inorganic arsenic-mediated epithelial-to-mesenchymal transition. Data Brief. 2017;13:6-9.
20 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
21 Expression of ZnT and ZIP zinc transporters in the human RPE and their regulation by neurotrophic factors. Invest Ophthalmol Vis Sci. 2008;49(3):1221-31.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.